Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 190M | 0 | 0 | 0 | 0 |
| Gross Profit | 188M | 0 | 0 | 0 | 0 |
| Operating Income | 15M | -188M | -41M | -24M | -32M |
| EBITDA | 28M | -174M | -37M | -22M | -30M |
| Net Income | 21M | -176M | -39M | -24M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$53.01
+0.00% today
Window Change
-34.89%
Window
Jun 23, 2025 → May 18, 2026
Coverage: 227 bars · Jun 23, 2025 → May 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Soleno Therapeutics, Inc. (SLNO) is a Healthcare stock with a market cap of $2.73B and listed on NASDAQ. The stock last traded around $53.01 and down 34.9% across the available one-year price window (Jun 23, 2025 → May 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +109.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +109.4%, free cash flow +167.4% with operating margin 5.4% and ROIC 2.0%. Valuation already assumes a fairly strong business story at P/E 134.6 and price/sales 14.4. Stock Foundry combines SLNO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLNO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLNO Max Drawdown
-66.04%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLNO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$30.9M
-28.4% YoY
Free Cash Flow
-$27.8M
-33.7% YoY
Revenue Growth
+0.0%
EPS Growth
+109.4%
Gross Margin
98.6%
Net Margin
11.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 190M | 0 | 0 | 0 | 0 |
| Gross Profit | 188M | 0 | 0 | 0 | 0 |
| Operating Income | 15M | -188M | -41M | -24M | -32M |
| EBITDA | 28M | -174M | -37M | -22M | -30M |
| Net Income | 21M | -176M | -39M | -24M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70M | 88M | 170M | 15M | 21M |
| Total Assets | 564M | 331M | 181M | 26M | 36M |
| Total Liabilities | 114M | 86M | 23M | 16M | 18M |
| Shareholder Equity | 450M | 245M | 158M | 10M | 18M |
| Total Debt | 3M | 53M | 403K | 155K | 457K |
| Net Debt | -67M | -35M | -169M | -14M | -21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
-33.6% YoY
Capital Expenditures
22K
-69.2% YoY
Free Cash Flow
28M
-33.7% YoY
Key ratios
Gross Margin
98.6%
Operating Margin
5.4%
Net Margin
11.0%
ROE
5.9%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.